摘要:
The invention relates to 17-methylene steroids, process for their production and pharmaceutical compositions that contain these compounds.The compounds according to the invention have a hybrid-type profile of action in the sense that they act as inhibitors of 5α-reductase and simultaneously as gestagens. They are therefore suitable for treating diseases that are the result of elevated androgen levels in certain organs and tissues in men and women. Together with other hormonal substances, such as an estrogen, testosterone or a strong androgen, the compounds according to the invention are suitable as contraceptive agents for women and for men.
摘要:
Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
摘要:
The invention relates to new C13-substituted estra-1,3,5(10)-trien-3-yl sulfamates of general formula I, wherein R1 represents an acyl residue, oxycarbonyl residue, aminocarbonyl residue, sulfonyl residue, or aminosulfonyl residue, and R15 represents ethyl, methods of preparing same, and pharmaceutical compositions containing these compounds. The compounds of the invention of general formula I inhibit the activity of steroid sulfatase (EC 3.1.6.2) and do not exhibit any estrogenic effect.
摘要:
The invention concerns pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives as active ingredients which carry a group of the general formula R—SO2—O— at their C3 position wherein R is a R1R2N group wherein R1 and R2 are independent of each other and represent a hydrogen atom, a C1-C5 alkyl radical or, together with the N atom, a polymethylene imino radical containing 4 to 6 C atoms, or a morpholino radical. The preparations according to the invention can be used for hormonal contraception and for hormon replacement therapy (HRT). They exhibit a low hepatic estrogenity.
摘要:
Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
摘要:
The invention relates to the use of estriol as the sole active ingredient for the production of a transdermal medicament which continuously releases the active ingredient for the treatment of climacteric osteoporosis. It has been shown according to the invention that estriol, which has up until now been thought ineffective for the treatment of climacteric osteoporosis, develops strong anti-osteoporotic effectiveness upon continuous transdermal application.
摘要:
14.alpha.,17.alpha.-(Propano-and 17.sup.2 -propeno)-estratrienes of general formula I ##STR1## in which R.sup.1 means a hydrogen atom, a methyl or an acyl group with 1-12 carbon atoms,R.sup.2 means a hydrogen atom or an acyl group with 1-12 carbon atoms and ##STR2## a C--C single or double bond. The new compounds of general formula I are estrogen effective just as ethinyl estradiol.
摘要:
This invention relates to new vasopressin and vasotocin derivatives of general formula I ##STR1## in which A stands for the radical Mca (=3-mercapto-3,3-cyclpentamethylenepropionyl radical) or for the radical Mpa (=3-mercaptopropionyl radical),B stands for the amino acid radicals D-Tyr, D-Tyr(Et), D-Phe, Tyr(OMe), D-lle, D-Trp, or the radical of a hydrophobic D-amino acid, andC stands for phenylalanine (Phe; vasopressin derivatives) or isoleucine (lle; vasotocin derivatives).They have a high activity toward the oxytocin and the V-vasopressin receptors and can be used for the production of pharmaceutical agents.
摘要:
A process of cyclizing compounds of formula II ##STR1## wherein K, V', R.sup.1 and 1 are as herein defined, is described whereby a compound of formula IVa is produced ##STR2## wherein K, V', R.sup.1, Q, S and 1 are as herein defined. The compounds of formula IVa are useful intermediates in the production of compounds of formula I ##STR3## wherein ring A, B, G, V, Z, R.sup.1 and R.sup.2 are as herein defined.
摘要:
There are provided 13-alkyl-11beta-phenyl-gonanes of formula I ##STR1## wherein Z is an oxygen atom or N--OH;R.sup.2 is alpha- or beta-position methyl or ethyl;R.sup.1 is selected from heteroaryl radicals, cycloalkyl radicals, cycloalkenyl radicals, aryl radicals, alkenyl radicals, and alkyl radicals where R.sup.2 is in the alpha-position and an ethyl radical where R.sup.2 is in the beta-position; andR.sup.3 and R.sup.4 are selected from one of two different groups of substituent pairs, the group from which the selection is made being determined by the position of R.sup.2.
摘要翻译:提供式I的13-烷基-11β-苯基 - 正膦(I)其中Z是氧原子或N-OH; R2是α-或β-位甲基或乙基; R 1选自杂芳基,环烷基,环烯基,芳基,烯基和其中R2为α-位的烷基和R2为β-位的乙基; 并且R3和R4选自两个不同取代基组之一,进行选择的基团由R2的位置确定。